- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02332655
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Kennedy Krieger Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Participants with Sturge-Weber syndrome brain involvement as defined on neuroimaging (n=10 subjects, male and female, ages 1 month to 45 years of age) and the following:
- Documentation of a diagnosis of drug resistant epilepsy as evidenced by failure to control seizures despite appropriate trial of two or more AEDs at therapeutic doses. Drug resistant epilepsy for this study is defined as: At least 1 reported quantifiable (no cluster or innumerable) defined seizure with motor signs per month for at least 3 months prior to initial visit and during the period between Visit 1 (Screening Visit) and Visit 2 (Baseline Visit), as per data captured in daily seizure diaries. These can be focal seizures, focal seizures with impaired consciousness, myoclonic seizures, generalized, and secondarily generalized seizures.
- Between 1-5 baseline anti-epileptic drugs at stable doses for a minimum of 4 weeks prior to enrollment. Vagus nerve stimulator (VNS), ketogenic diet and modified Atkins diet do not count toward this limit.
- VNS must be on stable settings for a minimum of 3 months prior to enrollment.
- If on ketogenic or Atkins diet, must be on stable ratio for a minimum of 3 months prior to enrollment.
- Previous subjects who failed at any point to meet continuation criteria and withdrew early may be considered for re-enrollment under a new subject ID as long as the above inclusion criteria are met. The determination of whether to re-enroll will be made by the PI and sponsor on a case-by-case basis. Re-enrollment can occur no earlier than 4 weeks after the final, post-weaning follow-up visit under the old subject ID.
Written informed consent obtained from the patient or the patient's legal representative must be obtained prior to beginning treatment.
Exclusion Criteria:
- Patients with seizures secondary to metabolic, toxic, infectious or psychogenic disorder or drug abuse or current seizures related to an acute medical illness.
- Presence of only non-motor partial seizures (without limb or facial movements, eye deviation or head turning)
- Patients who require rescue medication during the Baseline phase for more than 6 days.
Patients with any severe and/or uncontrolled medical conditions at randomization such as:
- liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis [i.e. quantifiable hepatitis B virus (HBV)-DNA and/or positive HbsAg, quantifiable hepatitis C virus (HCV)-RNA]
- Uncontrolled diabetes as defined by fasting serum glucose > 1.5
- Active (acute or chronic) or uncontrolled severe infections.
- Patients with an active, bleeding diathesis.
- Patients who have had a major surgery or significant traumatic injury within 4 weeks of study entry. Patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study.
- Patients who change the dose of the AEDs during 4 weeks before screening or during the baseline period.
- Prior treatment with any investigational drug within the preceding 4 weeks prior to study entry.
- Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study. Those in foster care, unable to keep follow-up appointments, maintain close contact with Principal Investigator, or complete all necessary studies to maintain safety.
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cannabidiol
All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis.
The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.
|
Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given. The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Seizures Per Month
Time Frame: Measured within 56 days before baseline and 56 days before week 14
|
A baseline seizure frequency was recorded for each subject in a diary for eight weeks prior to investigational drug initiation and parents/caregivers documented seizures on a daily basis throughout the trial using a seizure log.
For assessing the efficacy of CBD, the investigator counted the change in frequency of seizures per month.
The number of seizures within 56 days of the baseline and the number of seizures within 56 days of week 14 were calculated.
Higher seizure frequency indicates worse outcome.
This outcome is measured as the change in number of seizures per month between the baseline and week 14 time points.
|
Measured within 56 days before baseline and 56 days before week 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in Seizure Frequency at Most Recent Visit on CBD Compared With Baseline
Time Frame: Measured at Baseline and most recent visit within 1 year
|
The percentage change, between the seizure frequency per month reported at baseline compared to seizure frequency per month at the subject's most recent visit, on CBD was calculated.
Higher positive percentage change in seizure frequency per month would indicate better outcome.
Positive values indicate a decrease in seizure frequency.
|
Measured at Baseline and most recent visit within 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne M Comi, MD, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Disease
- Brain Ischemia
- Infarction
- Stroke
- Brain Infarction
- Hemangioma
- Neoplasms, Vascular Tissue
- Neurocutaneous Syndromes
- Angiomatosis
- Syndrome
- Klippel-Trenaunay-Weber Syndrome
- Sturge-Weber Syndrome
- Brain Stem Infarctions
- Anticonvulsants
- Cannabidiol
Other Study ID Numbers
- IRB00029264
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sturge-Weber Syndrome
-
Johns Hopkins UniversityVascular Birthmarks FoundationCompletedEpilepsy | Sturge Weber SyndromeUnited States
-
University of California, IrvineMainz UniversityCompletedSturge - Weber Syndrome (SWS)United States
-
Wills EyeUniversity of Medicine and Dentistry of New JerseyTerminatedSturge Weber Syndrome | Port-wine MarkUnited States
-
Baylor College of MedicineNovartis PharmaceuticalsWithdrawnSturge Weber SyndromeUnited States
-
Clinica Universidad de Navarra, Universidad de...Completed
-
Qlaris Bio, Inc.CompletedOcular Hypertension | Glaucoma | Glaucoma Congenital | Sturge-Weber Syndrome (SWS)United States
-
University of Illinois at ChicagoWayne State University; Boston Children's Hospital; Duke University; University... and other collaboratorsRecruitingSturge-Weber SyndromeUnited States
-
University Hospital, ToursCompletedPort Wine Stain | Parkes Weber Syndrome | Klippel Trenaunay SyndromeFrance
-
Wayne State UniversityNational Institutes of Health (NIH)Recruiting
-
Hugo W. Moser Research Institute at Kennedy Krieger...Baylor College of Medicine; New York University; National Institute of Neurological... and other collaboratorsActive, not recruitingSturge-Weber SyndromeUnited States
Clinical Trials on Cannabidiol
-
Marius HenriksenCompleted
-
University of Colorado, BoulderNot yet recruitingDepression | Pain | Sleep | AnxietyUnited States
-
University of Colorado, BoulderNot yet recruiting
-
University of Colorado, BoulderNational Institute on Drug Abuse (NIDA)Not yet recruitingCannabis Use Disorder
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
Zynerba Pharmaceuticals, Inc.Enrolling by invitationFragile X SyndromeUnited States, United Kingdom, New Zealand, Australia
-
Elena PopeAvicanna IncWithdrawnPain | Epidermolysis Bullosa | ItchCanada
-
Yale UniversityNational Institute on Drug Abuse (NIDA); VA Connecticut Healthcare SystemRecruiting
-
University of Mississippi, OxfordUnknown
-
University of Northern ColoradoCompleted